ArticleTherapeutic advances in gastroenterology2025

Clinical insights into IL-23 inhibition: risankizumab for Crohn's disease through a systematic review and meta-analysis of randomized controlled trials.

Po-Feng Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.